Therapy Areas: Infectious Diseases
Nona Biosciences signs licensing agreement with University of Alabama at Birmingham
20 February 2025 - US biotechnology company Nona Biosciences announced on Wednesday that it has signed a licensing agreement with the University of Alabama at Birmingham (UAB) to support its research ...
ImmunityBio's ANKTIVA receives EMA review for BCG-unresponsive bladder cancer treatment
27 January 2025 - ImmunityBio Inc (NASDAQ: IBRX) announced on Monday that the European Medicines Agency (EMA) has accepted its marketing authorisation application for ANKTIVA (nogapendekin alfa inbaki...
hVIVO signs LOI for landmark Phase 3 whooping cough vaccine trial with ILiAD Biotechnologies
27 January 2025 - hVIVO plc (AIM: HVO), a contract research organisation specialising in human challenge clinical trials, announced on Monday that it has signed a letter of intent with ILiAD Biotechno...
hVIVO completes pilot study for hMPV challenge model
13 January 2025 - hVIVO plc (AIM: HVO), a contract research organisation specialising in infectious and respiratory disease trials, announced on Monday that it has completed a successful pilot charact...
Abingdon Health subsidiary awarded GBP500,000 contract
8 January 2025 - Abingdon Health plc (AIM: ABDX), a lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announced on Wednesday that its subsidiary, CS ...
Ondine Biomedical enrolls first patient in US Phase 3 trial
30 December 2024 - Ondine Biomedical Inc (LON: OBI), a Canadian life sciences company, announced on Monday that it has enrolled its first patient in the US Phase 3 clinical trial for its Light-Activat...